Nand, S <br/><br/>
Leukemogenic risk of hydroxyurea therapy in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis.  [electronic resource] 

 -  American journal of hematology  May 1996 
 - 42-6 p.  digital 
<br/><br/> Publication Type: Comparative Study; Journal Article 
<br/><br/><label>ISSN: </label>0361-8609 
<br/><br/><label>Standard No.: </label>10.1002/(SICI)1096-8652(199605)52:1<42::AID-AJH7>3.0.CO;2-6  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Acute Disease<br/>Anemia, Refractory, with Excess of Blasts--chemically induced<br/>Busulfan--adverse effects<br/>Cell Transformation, Neoplastic--drug effects<br/>Chlorambucil--adverse effects<br/>Cohort Studies<br/>Disease Progression<br/>Drug Therapy, Combination<br/>Enzyme Inhibitors--adverse effects<br/>Female<br/>Humans<br/>Hydroxyurea--adverse effects<br/>Incidence<br/>Interferon-alpha--adverse effects<br/>Leukemia--chemically induced<br/>Leukemia, Radiation-Induced--etiology<br/>Male<br/>Melphalan--adverse effects<br/>Middle Aged<br/>Phlebotomy<br/>Phosphorus Radioisotopes--adverse effects<br/>Polycythemia Vera--drug therapy<br/>Preleukemia--epidemiology<br/>Primary Myelofibrosis--drug therapy<br/>Retrospective Studies<br/>Ribonucleotide Reductases--antagonists & inhibitors<br/>Risk<br/>Thrombocythemia, Essential--drug therapy